 Bennett Chin
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 25 | 2022 | 158 | 3.500 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 19 | 2014 | 75 | 2.360 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 85 | 1.760 |
Why?
| | Fluorodeoxyglucose F18 | 15 | 2019 | 115 | 1.680 |
Why?
| | Iodine Radioisotopes | 8 | 2023 | 126 | 1.430 |
Why?
| | Organometallic Compounds | 6 | 2023 | 98 | 1.390 |
Why?
| | Positron-Emission Tomography | 8 | 2024 | 260 | 1.160 |
Why?
| | Tomography, Emission-Computed | 9 | 2004 | 58 | 1.110 |
Why?
| | Image Enhancement | 4 | 2007 | 158 | 0.770 |
Why?
| | Heart | 8 | 2014 | 613 | 0.690 |
Why?
| | 3-Iodobenzylguanidine | 3 | 2023 | 6 | 0.670 |
Why?
| | Fluorine Radioisotopes | 3 | 2017 | 10 | 0.640 |
Why?
| | Thallium Radioisotopes | 5 | 1999 | 7 | 0.580 |
Why?
| | Radionuclide Imaging | 13 | 2022 | 115 | 0.560 |
Why?
| | Contrast Media | 6 | 2014 | 347 | 0.550 |
Why?
| | Positron Emission Tomography Computed Tomography | 5 | 2022 | 67 | 0.540 |
Why?
| | Urinary Retention | 1 | 2016 | 19 | 0.530 |
Why?
| | Carcinosarcoma | 1 | 2016 | 17 | 0.530 |
Why?
| | Paraganglioma | 3 | 2023 | 46 | 0.530 |
Why?
| | Leucine | 1 | 2017 | 102 | 0.530 |
Why?
| | Oxyquinoline | 2 | 2007 | 3 | 0.500 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 92 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 577 | 0.460 |
Why?
| | Whole Body Imaging | 2 | 2014 | 19 | 0.440 |
Why?
| | Gated Blood-Pool Imaging | 2 | 2007 | 5 | 0.440 |
Why?
| | Leukemia L1210 | 2 | 2012 | 7 | 0.440 |
Why?
| | Gallium Radioisotopes | 2 | 2023 | 12 | 0.430 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 33 | 0.390 |
Why?
| | Chloroquine | 1 | 2012 | 52 | 0.380 |
Why?
| | Myocardial Infarction | 3 | 2007 | 932 | 0.380 |
Why?
| | Prostatic Neoplasms | 3 | 2016 | 913 | 0.380 |
Why?
| | Thyroid Neoplasms | 3 | 2016 | 271 | 0.380 |
Why?
| | Technetium Tc 99m Sestamibi | 8 | 2016 | 12 | 0.370 |
Why?
| | Phenylalanine | 1 | 2011 | 57 | 0.370 |
Why?
| | Isoenzymes | 1 | 2012 | 283 | 0.360 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2023 | 81 | 0.350 |
Why?
| | Pheochromocytoma | 2 | 2023 | 54 | 0.340 |
Why?
| | Coronary Circulation | 5 | 2002 | 134 | 0.330 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2007 | 371 | 0.330 |
Why?
| | Phantoms, Imaging | 7 | 2015 | 123 | 0.330 |
Why?
| | Electrocardiography | 2 | 2014 | 561 | 0.330 |
Why?
| | Tissue Distribution | 3 | 2017 | 285 | 0.320 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1690 | 0.310 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2009 | 102 | 0.310 |
Why?
| | Aldehydes | 1 | 2009 | 138 | 0.310 |
Why?
| | Radiation Dosage | 3 | 2015 | 133 | 0.310 |
Why?
| | Breast Neoplasms | 3 | 2017 | 1846 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 7 | 2008 | 2272 | 0.290 |
Why?
| | Lung Neoplasms | 3 | 2016 | 2159 | 0.290 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2005 | 224 | 0.260 |
Why?
| | Feasibility Studies | 6 | 2009 | 735 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2004 | 850 | 0.260 |
Why?
| | Humans | 45 | 2024 | 114045 | 0.250 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 266 | 0.250 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 237 | 0.250 |
Why?
| | Gamma Cameras | 1 | 2005 | 7 | 0.250 |
Why?
| | Radiometry | 2 | 2017 | 41 | 0.250 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 59 | 0.250 |
Why?
| | Stomach Neoplasms | 2 | 2022 | 65 | 0.240 |
Why?
| | Intercostal Muscles | 1 | 2004 | 3 | 0.240 |
Why?
| | Indium Radioisotopes | 3 | 1999 | 13 | 0.230 |
Why?
| | Somatostatin | 3 | 2016 | 52 | 0.230 |
Why?
| | Data Curation | 1 | 2024 | 11 | 0.230 |
Why?
| | Vocal Cord Paralysis | 1 | 2003 | 21 | 0.220 |
Why?
| | Vocal Cords | 1 | 2003 | 25 | 0.220 |
Why?
| | Thyrotropin | 1 | 2004 | 100 | 0.220 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2003 | 37 | 0.220 |
Why?
| | Digestive System Neoplasms | 1 | 2003 | 8 | 0.220 |
Why?
| | Carcinoma, Papillary | 1 | 2003 | 74 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3039 | 0.210 |
Why?
| | Atherosclerosis | 1 | 2007 | 342 | 0.210 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2002 | 14 | 0.210 |
Why?
| | Myocardial Contraction | 2 | 2002 | 318 | 0.210 |
Why?
| | Cell Line, Tumor | 3 | 2017 | 2700 | 0.200 |
Why?
| | Animals | 18 | 2019 | 31565 | 0.200 |
Why?
| | Radioisotopes | 1 | 2022 | 28 | 0.200 |
Why?
| | Receptors, Peptide | 1 | 2022 | 15 | 0.200 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2022 | 6 | 0.200 |
Why?
| | Myocardial Stunning | 1 | 2002 | 5 | 0.200 |
Why?
| | Dobutamine | 1 | 2002 | 33 | 0.200 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 24 | 0.200 |
Why?
| | Mice | 8 | 2019 | 14843 | 0.190 |
Why?
| | Female | 27 | 2018 | 59324 | 0.170 |
Why?
| | Oxygen Consumption | 1 | 2003 | 587 | 0.170 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 2 | 1999 | 6 | 0.170 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 1999 | 38 | 0.160 |
Why?
| | Stem Cells | 1 | 2003 | 541 | 0.160 |
Why?
| | Middle Aged | 19 | 2016 | 26605 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2003 | 414 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2024 | 684 | 0.160 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1999 | 9 | 0.160 |
Why?
| | Receptors, Somatostatin | 1 | 1999 | 24 | 0.160 |
Why?
| | Thymus Neoplasms | 1 | 1999 | 20 | 0.160 |
Why?
| | Thymoma | 1 | 1999 | 29 | 0.160 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.160 |
Why?
| | Radiation Pneumonitis | 1 | 1999 | 24 | 0.160 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1999 | 115 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2022 | 721 | 0.160 |
Why?
| | Male | 24 | 2018 | 55396 | 0.150 |
Why?
| | Neoplasms | 1 | 2012 | 2086 | 0.150 |
Why?
| | Metal Nanoparticles | 1 | 2019 | 69 | 0.150 |
Why?
| | Brain Neoplasms | 2 | 2019 | 966 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 60 | 0.150 |
Why?
| | Sodium Pertechnetate Tc 99m | 1 | 1997 | 6 | 0.150 |
Why?
| | Myocardium | 1 | 2003 | 911 | 0.150 |
Why?
| | Coronary Disease | 2 | 2000 | 348 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 427 | 0.150 |
Why?
| | Frontal Lobe | 1 | 1998 | 141 | 0.150 |
Why?
| | Dipyridamole | 2 | 2002 | 25 | 0.150 |
Why?
| | Hematoma | 1 | 1997 | 50 | 0.140 |
Why?
| | Isotope Labeling | 2 | 2011 | 67 | 0.140 |
Why?
| | Smoking | 1 | 2004 | 1382 | 0.140 |
Why?
| | Transurethral Resection of Prostate | 1 | 2016 | 3 | 0.140 |
Why?
| | Safety | 1 | 2018 | 298 | 0.130 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 278 | 0.130 |
Why?
| | Dementia | 1 | 1998 | 186 | 0.130 |
Why?
| | Vasodilator Agents | 2 | 2002 | 302 | 0.130 |
Why?
| | Molecular Structure | 1 | 2017 | 434 | 0.120 |
Why?
| | Parathyroid Diseases | 1 | 2015 | 1 | 0.120 |
Why?
| | Thyroid Nodule | 1 | 2016 | 45 | 0.120 |
Why?
| | Sarcoidosis | 1 | 1997 | 133 | 0.120 |
Why?
| | Stroke Volume | 2 | 1997 | 513 | 0.120 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2015 | 25 | 0.120 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 256 | 0.120 |
Why?
| | Androstenes | 1 | 2015 | 11 | 0.120 |
Why?
| | Phenylthiohydantoin | 1 | 2015 | 40 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2015 | 66 | 0.120 |
Why?
| | Taxoids | 1 | 2015 | 93 | 0.120 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 40 | 0.120 |
Why?
| | Dogs | 4 | 2003 | 331 | 0.120 |
Why?
| | Mediastinum | 1 | 2014 | 20 | 0.110 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1144 | 0.110 |
Why?
| | Prednisone | 1 | 2015 | 229 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 477 | 0.110 |
Why?
| | Cardiomyopathies | 1 | 1997 | 298 | 0.110 |
Why?
| | Coronary Stenosis | 3 | 2002 | 39 | 0.110 |
Why?
| | Bone and Bones | 3 | 2009 | 277 | 0.110 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 98 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2014 | 191 | 0.110 |
Why?
| | Adult | 12 | 2014 | 30375 | 0.100 |
Why?
| | Aged | 11 | 2015 | 18969 | 0.100 |
Why?
| | Swine | 6 | 2003 | 687 | 0.090 |
Why?
| | Carbon Radioisotopes | 1 | 2011 | 36 | 0.090 |
Why?
| | Hemodynamics | 1 | 1996 | 1015 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 636 | 0.090 |
Why?
| | Time Factors | 2 | 2014 | 6077 | 0.090 |
Why?
| | Neoplasm Metastasis | 2 | 2004 | 521 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2003 | 415 | 0.090 |
Why?
| | Organ Specificity | 2 | 2019 | 266 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2007 | 2764 | 0.090 |
Why?
| | Thyroid Gland | 2 | 2016 | 85 | 0.090 |
Why?
| | Mice, Nude | 1 | 2012 | 628 | 0.090 |
Why?
| | Gadolinium | 4 | 2002 | 73 | 0.080 |
Why?
| | K562 Cells | 1 | 2009 | 73 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2007 | 4680 | 0.080 |
Why?
| | Glioblastoma | 1 | 2012 | 250 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1143 | 0.080 |
Why?
| | Metabolic Clearance Rate | 1 | 2008 | 102 | 0.080 |
Why?
| | Parathyroid Neoplasms | 2 | 1997 | 13 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2002 | 1162 | 0.070 |
Why?
| | Octreotide | 2 | 1999 | 25 | 0.070 |
Why?
| | Adenoma | 3 | 1998 | 187 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 1875 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 295 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2016 | 12521 | 0.070 |
Why?
| | Injections, Intravenous | 2 | 2003 | 198 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2008 | 1218 | 0.060 |
Why?
| | Molecular Probe Techniques | 1 | 2005 | 9 | 0.060 |
Why?
| | Miniaturization | 1 | 2005 | 23 | 0.060 |
Why?
| | Molecular Biology | 1 | 2005 | 56 | 0.060 |
Why?
| | Iodides | 1 | 2004 | 6 | 0.060 |
Why?
| | Equipment Failure Analysis | 1 | 2005 | 132 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2023 | 1032 | 0.060 |
Why?
| | Theophylline | 1 | 2004 | 60 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2004 | 82 | 0.060 |
Why?
| | Models, Animal | 2 | 2003 | 340 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2004 | 17 | 0.060 |
Why?
| | Artifacts | 1 | 2004 | 114 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 503 | 0.050 |
Why?
| | Neck | 1 | 2003 | 85 | 0.050 |
Why?
| | Metanephrine | 1 | 2023 | 2 | 0.050 |
Why?
| | Inhalation | 1 | 2003 | 26 | 0.050 |
Why?
| | Exhalation | 1 | 2003 | 34 | 0.050 |
Why?
| | Gadolinium DTPA | 1 | 2002 | 47 | 0.050 |
Why?
| | Chromogranin A | 1 | 2023 | 39 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6306 | 0.050 |
Why?
| | Movement | 1 | 2004 | 242 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 926 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 239 | 0.050 |
Why?
| | Intestines | 1 | 2004 | 325 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2007 | 2562 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1228 | 0.040 |
Why?
| | Radioimmunodetection | 1 | 1999 | 1 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2003 | 270 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1036 | 0.040 |
Why?
| | Cell Movement | 1 | 2003 | 863 | 0.040 |
Why?
| | Bone Neoplasms | 2 | 1999 | 191 | 0.040 |
Why?
| | Pilot Projects | 1 | 2003 | 1360 | 0.040 |
Why?
| | Organotechnetium Compounds | 1 | 1998 | 10 | 0.040 |
Why?
| | Salvage Therapy | 1 | 1999 | 127 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 1999 | 18 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 52 | 0.040 |
Why?
| | Mediastinal Neoplasms | 1 | 1999 | 32 | 0.040 |
Why?
| | Gardner Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Osteoma | 1 | 1998 | 2 | 0.040 |
Why?
| | Prostate-Specific Antigen | 2 | 2015 | 150 | 0.040 |
Why?
| | Gold | 1 | 2019 | 102 | 0.040 |
Why?
| | Retroperitoneal Space | 1 | 1997 | 14 | 0.040 |
Why?
| | HIV-1 | 1 | 2003 | 768 | 0.040 |
Why?
| | Cysteine | 1 | 1998 | 171 | 0.040 |
Why?
| | Carcinoid Tumor | 1 | 1997 | 23 | 0.040 |
Why?
| | Duodenal Neoplasms | 1 | 1997 | 19 | 0.040 |
Why?
| | Cardiac Volume | 1 | 1997 | 11 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2007 | 3498 | 0.040 |
Why?
| | Ventricular Function | 1 | 1997 | 57 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2003 | 592 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 590 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 219 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 1999 | 180 | 0.030 |
Why?
| | Choristoma | 1 | 1996 | 21 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 1997 | 172 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 70 | 0.030 |
Why?
| | Deoxyglucose | 1 | 1995 | 43 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 1995 | 31 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1206 | 0.030 |
Why?
| | Lung | 2 | 1999 | 3521 | 0.030 |
Why?
| | Radiography | 2 | 2015 | 803 | 0.030 |
Why?
| | Abiraterone Acetate | 1 | 2015 | 14 | 0.030 |
Why?
| | Kallikreins | 1 | 2015 | 28 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1331 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 149 | 0.030 |
Why?
| | Benzamides | 1 | 2015 | 168 | 0.030 |
Why?
| | Risk Factors | 3 | 2015 | 8614 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 1999 | 4392 | 0.030 |
Why?
| | Exercise Test | 1 | 1996 | 547 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 1999 | 1257 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 1993 | 46 | 0.030 |
Why?
| | Infusion Pumps, Implantable | 1 | 1993 | 20 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 618 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9049 | 0.030 |
Why?
| | Hepatic Artery | 1 | 1993 | 49 | 0.030 |
Why?
| | Erythrocytes | 1 | 1997 | 568 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 813 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 1996 | 545 | 0.030 |
Why?
| | Biopsy | 1 | 2016 | 1024 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1078 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3315 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 959 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2247 | 0.020 |
Why?
| | HIV Infections | 1 | 2003 | 2453 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1996 | 3003 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2314 | 0.020 |
Why?
| | Brain | 1 | 1999 | 2355 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2371 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 2958 | 0.020 |
Why?
| | Adolescent | 2 | 2018 | 17800 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2004 | 26 | 0.010 |
Why?
| | Subtraction Technique | 1 | 2004 | 24 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2004 | 225 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 2004 | 150 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 109 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 122 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 159 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 924 | 0.010 |
Why?
| | Virus Replication | 1 | 2003 | 395 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 234 | 0.010 |
Why?
| | Vasodilation | 1 | 2002 | 418 | 0.010 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2000 | 146 | 0.010 |
Why?
| | Prostatectomy | 1 | 1999 | 97 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 532 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2003 | 497 | 0.010 |
Why?
| | Zollinger-Ellison Syndrome | 1 | 1997 | 2 | 0.010 |
Why?
| | Gastrins | 1 | 1997 | 8 | 0.010 |
Why?
| | Radionuclide Angiography | 1 | 1997 | 2 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 3861 | 0.010 |
Why?
| | Research Design | 1 | 2002 | 919 | 0.010 |
Why?
| | Esophagus | 1 | 1996 | 224 | 0.010 |
Why?
| | Heart Diseases | 1 | 1997 | 329 | 0.010 |
Why?
| | Technetium | 1 | 1993 | 8 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 123 | 0.010 |
Why?
| | Liver | 1 | 1993 | 1633 | 0.000 |
Why?
| | Prospective Studies | 1 | 1993 | 6195 | 0.000 |
Why?
|
|
Chin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|